Navigation Links
QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline
Date:7/24/2014

e calreticulin (CALR) biomarker, implicated in an estimated 15% of cases of myeloproliferative neoplasms (MPNs), which involve overproduction of blood cells. The CALR diagnostic that is under development is expected to be highly complementary to QIAGEN's currently marketed kits for a key mutation of the Janus kinase 2 (JAK2) gene.

About QIAGEN 

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of March 31, 2014, QIAGEN employed approximately 4,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that in
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
2. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
3. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
4. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
5. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
6. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
7. QIAGEN Significantly Expands its Offering of Assay Panels for Next-generation Sequencing (NGS) Complemented by Ingenuity Analysis and Interpretation Capabilities
8. Exosome Diagnostics and QIAGEN Partner to Launch Comprehensive Line of Biofluid Nucleic Acid Kits to Address Limitations of Tissue Biopsy in Clinical Research Market
9. Financial Results, Appointments, Earnings Conferences, and Partnerships - Research Report on New Oriental Education & Technology, Acacia Research, DeVry, Capella Education, and Qiagen NV
10. QIAGEN Offers Clinical Labs Early Access to New Ingenuity Solution for Streamlined Interpretation of Patient Sequencing Data
11. Maverix Biomics Forms Strategic Co-Marketing Alliance with QIAGEN
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014   Fruit Street Health (Fruit Street), ... round of funding. The round, which ... series of individual investors, the majority of whom are ... initial round are; Houston Cardiology Consultants Partner Asif ... Childs, Rapha Family Medicine Practice Owner Frances Ilozue ...
(Date:9/18/2014)... N.J. , Sept. 18, 2014  ADM ... Gianluca DeNovi , Ph.D. to its corporate Advisory ... is an instructor at the Harvard Medical School ... of Rome.  He received his Masters degree in ... Control Systems from the University of Bologna. After spending ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
Breaking Medicine Technology:Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 2Fruit Street Health Secures First Round Of Seed Funding Led By Group Of Medical Industry And Technology Leaders 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
(Date:9/18/2014)... don,t worry, it,s a good thing! As scientists have ... bad. Many active enzymes and bacteria are merely benign, ... important part of our digestive system or can help ... an opportunistic yeast pathogen and model organism for research, ... ecosystem. However, when our immune system is stressed on ...
(Date:9/18/2014)... Non-governmental stakeholders will convene a one-day conference at ... George Washington University on September 25, 2014 to discuss ... towards GHSA implementation. The purpose of this event is ... over the next five years, including action plans to ... 2014 launch of the GHSA, international organizations and more ...
(Date:9/18/2014)... (September 18, 2014) The National Institutes of ... from a four-year, $1.3 million grant to the Los ... the research and development of a vaccine to protect ... Methicillin-resistant Staphylococcus aureus (MRSA). , The ... the NIH awarded the grant to LA BioMed infectious ...
(Date:9/18/2014)... DURHAM, N.C. Dangerous new pathogens such as the ... even ancient scourges such as the bubonic plague are ... body responds to infections. , In a study published ... , researchers at Duke Medicine and Duke-NUS Graduate Medical ... cause bubonic plague hitchhike on immune cells in the ...
(Date:9/18/2014)... ChopChop founder Sally Sampson is challenging former ... Massachusetts’s winner of the First Lady’s Healthy Lunchtime Challenge, to ... Eastern bean dip. Watch as Bill and Yonah cook side-by-side ... own healthy dips at home. The cooking demonstration will take ... Talk About Food Festival in Copley Square on September ...
Breaking Medicine News(10 mins):Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2Health News:New insights on an ancient plague could improve treatments for infections 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 2Health News:Award-Winning Cooking Magazine for Kids Challenges Former White House Pastry Chef and 10-Year-Old Chef to Cook Up a Healthy Snack 3
... surveillance, planning and interagency coordinationWASHINGTON, May 8 Environmental ... the Natural Resources Defense Council (NRDC) praised legislation introduced ... climate change. The bill is sponsored by the ... Commerce Committee,s Subcommittee on Health , U.S. Rep. ...
... This Sunday, individuals all over the nation ... women who gave them life: their mothers. While people in ... International Breast Milk Project (IBMP) hopes to inspire some to ... that helps mothers in the United States send their breast ...
... Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals and ... $10.6 billion for the quarter ended March 31, 2009, ... year. Operating income in the first quarter was ... of 2008. Declines in the financial markets impacted ...
... May 8 Misonix, Inc. (Nasdaq: MSON ... technology, which in Europe is used for the ablation ... has entered into a definitive, 5-year distribution agreement with ... in Barcarena, Portugal, expanding on and replacing a previous ...
... - Majority have not changed their behavior or lifestyle ... May 8 A new national study among 1,477 ... become less concerned about the impact that the H1N1 ... http://www.newscom.com/cgi-bin/prnh/20071204/NYTU133LOGO )Results ...
... Family, Inc. (Nasdaq: AFAM ), a leading regional ... Yarmuth, President and Chief Executive Officer, and Steve Guenthner, Senior ... at two upcoming investor conferences. The first presentation will ... Stock Conference at the Four Seasons Hotel in Chicago, IL., ...
Cached Medicine News:Health News:New Bill to Fund Climate Change and Public Health Preparedness Praised by Environmental and Health Groups 2Health News:New Bill to Fund Climate Change and Public Health Preparedness Praised by Environmental and Health Groups 3Health News:New Bill to Fund Climate Change and Public Health Preparedness Praised by Environmental and Health Groups 4Health News:International Breast Milk Project Helps Mothers Worldwide 2Health News:Kaiser Foundation Health Plan and Hospitals Report First Quarter 2009 Financial Results 2Health News:Kaiser Foundation Health Plan and Hospitals Report First Quarter 2009 Financial Results 3Health News:Misonix Announces New HIFU Distribution Agreement For Portugal 2Health News:Misonix Announces New HIFU Distribution Agreement For Portugal 3Health News:Docs Are Becoming Less Concerned About H1N1 Swine Flu 2Health News:Docs Are Becoming Less Concerned About H1N1 Swine Flu 3Health News:Docs Are Becoming Less Concerned About H1N1 Swine Flu 4Health News:Almost Family to Present at Two Upcoming Conferences 2
For use with catalog #0540....
Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
Antigenic Total Protein S, ELISA Method...
Colorimetric Assay of Antithrombin III Activity by STA© Analyzers. Bovine thrombin ~12NIH units/mL, freeze-dried....
Medicine Products: